These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 8944278)

  • 1. Lipid formulations of amphotericin b in the treatment of experimental visceral leishmaniasis due to Leishmania infantum.
    Gangneux JP; Sulahian A; Garin YJ; Derouin F
    Trans R Soc Trop Med Hyg; 1996; 90(5):574-7. PubMed ID: 8944278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapy of visceral leishmaniasis due to Leishmania infantum: experimental assessment of efficacy of AmBisome.
    Gangneux JP; Sulahian A; Garin YJ; Farinotti R; Derouin F
    Antimicrob Agents Chemother; 1996 May; 40(5):1214-8. PubMed ID: 8723469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the efficacies of various formulations of amphotericin B against murine visceral leishmaniasis.
    Mullen AB; Carter KC; Baillie AJ
    Antimicrob Agents Chemother; 1997 Oct; 41(10):2089-92. PubMed ID: 9333030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of low doses of amphotericin B plus allicin against experimental visceral leishmaniasis.
    Corral MJ; Serrano DR; Moreno I; Torrado JJ; Domínguez M; Alunda JM
    J Antimicrob Chemother; 2014 Dec; 69(12):3268-74. PubMed ID: 25096077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biodistribution and
    Iman M; Huang Z; Alavizadeh SH; Szoka FC; Jaafari MR
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic and immunomodulatory activities of short-course treatment of murine visceral leishmaniasis with KALSOME™10, a new liposomal amphotericin B.
    Asad M; Bhattacharya P; Banerjee A; Ali N
    BMC Infect Dis; 2015 Apr; 15():188. PubMed ID: 25884796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of liposomal amphotericin B (AmBisome) against Leishmania infantum and tissue distribution in mice.
    Gradoni L; Davidson RN; Orsini S; Betto P; Giambenedetti M
    J Drug Target; 1993; 1(4):311-6. PubMed ID: 8069573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complete cure of experimental visceral leishmaniasis with amphotericin B in stearylamine-bearing cationic liposomes involves down-regulation of IL-10 and favorable T cell responses.
    Banerjee A; De M; Ali N
    J Immunol; 2008 Jul; 181(2):1386-98. PubMed ID: 18606693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liposomal amphotericin B in the treatment of visceral leishmaniasis in immunocompetent patients.
    Minodier P; Retornaz K; Horelt A; Garnier JM
    Fundam Clin Pharmacol; 2003 Apr; 17(2):183-8. PubMed ID: 12667228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic effect of reference antileishmanial agents in murine visceral leishmaniasis due to Leishmania infantum.
    Buffet PA; Garin YJ; Sulahian A; Nassar N; Derouin F
    Ann Trop Med Parasitol; 1996 Jun; 90(3):295-302. PubMed ID: 8758143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of experimental visceral leishmaniasis with amphotericin B in stable albumin microspheres.
    Sánchez-Brunete JA; Dea MA; Rama S; Bolás F; Alunda JM; Raposo R; Méndez MT; Torrado-Santiago S; Torrado JJ
    Antimicrob Agents Chemother; 2004 Sep; 48(9):3246-52. PubMed ID: 15328080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacious treatment of experimental leishmaniasis with amphotericin B-arabinogalactan water-soluble derivatives.
    Golenser J; Frankenburg S; Ehrenfreund T; Domb AJ
    Antimicrob Agents Chemother; 1999 Sep; 43(9):2209-14. PubMed ID: 10471566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antileishmanial activity of liposome-encapsulated amphotericin B in hamsters and monkeys.
    Berman JD; Hanson WL; Chapman WL; Alving CR; Lopez-Berestein G
    Antimicrob Agents Chemother; 1986 Dec; 30(6):847-51. PubMed ID: 3813512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of the activities of three amphotericin B lipid formulations against experimental visceral and cutaneous leishmaniasis.
    Yardley V; Croft SL
    Int J Antimicrob Agents; 2000 Feb; 13(4):243-8. PubMed ID: 10755238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidemiological, clinical & pharmacological study of antimony-resistant visceral leishmaniasis in Bihar, India.
    Thakur CP; Narayan S; Ranjan A
    Indian J Med Res; 2004 Sep; 120(3):166-72. PubMed ID: 15489554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Digitoxigenin presents an effective and selective antileishmanial action against Leishmania infantum and is a potential therapeutic agent for visceral leishmaniasis.
    Freitas CS; Oliveira-da-Silva JA; Lage DP; Costa RR; Mendonça DVC; Martins VT; Reis TAR; Antinarelli LMR; Machado AS; Tavares GSV; Ramos FF; Coelho VTS; Brito RCF; Ludolf F; Chávez-Fumagalli MA; Roatt BM; Ramos GS; Munkert J; Ottoni FM; Campana PRV; Humbert MV; Coimbra ES; Braga FC; Pádua RM; Coelho EAF
    Parasitol Res; 2021 Jan; 120(1):321-335. PubMed ID: 33191446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amphotericin B: A drug of choice for Visceral Leishmaniasis.
    Kumari S; Kumar V; Tiwari RK; Ravidas V; Pandey K; Kumar A
    Acta Trop; 2022 Nov; 235():106661. PubMed ID: 35998680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the in vitro and in vivo antileishmanial activity of a chloroquinolin derivative against Leishmania species capable of causing tegumentary and visceral leishmaniasis.
    Soyer TG; Mendonça DVC; Tavares GSV; Lage DP; Dias DS; Ribeiro PAF; Perin L; Ludolf F; Coelho VTS; Ferreira ACG; Neves PHAS; Matos GF; Chávez-Fumagalli MA; Coimbra ES; Pereira GR; Coelho EAF; Antinarelli LMR
    Exp Parasitol; 2019 Apr; 199():30-37. PubMed ID: 30817917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparative evaluation of amphotericin B and sodium antimony gluconate, as first-line drugs in the treatment of Indian visceral leishmaniasis.
    Thakur CP; Narayan S
    Ann Trop Med Parasitol; 2004 Mar; 98(2):129-38. PubMed ID: 15035723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of lapachol on treatment of cutaneous and visceral leishmaniasis.
    Araújo IAC; de Paula RC; Alves CL; Faria KF; Oliveira MM; Mendes GG; Dias EMFA; Ribeiro RR; Oliveira AB; Silva SMD
    Exp Parasitol; 2019 Apr; 199():67-73. PubMed ID: 30797783
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.